Nls pharmaceutics announces publication of new patent application for next-gen dual non-sulfonamide orexin receptor agonists (doxa)

Zurich, switzerland / accesswire / june 11, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (pct/wo2024115797) by aexon labs with the world intellectual property organization (wipo).
NLSP Ratings Summary
NLSP Quant Ranking